Evidence map›Paper›PMID 36141337›Full record

ArticleHealthcare (Basel, Switzerland)2022

Effect of Lockdown and Mass Testing for the SARS-CoV-2 Omicron Epidemic on Reducing New Infections in Shenzhen, China.

Xinxin Han, Xiaotong Li, Bin Zhu, Wenjing Zhao, Jie Huang, Gang Liu, Dongfeng Gu

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xinxin HanSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0000-0002-6968-1399
Xiaotong LiSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.
Bin ZhuSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0000-0002-0091-6356
Wenjing ZhaoSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.
Jie HuangSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.
Gang LiuShenzhen Center for Disease Prevention and Control, Shenzhen 518020, China.
Dongfeng GuSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China.
Southern University of Science and Technology · CNHong Kong University of Science and Technology · HKShenzhen Center for Disease Control and Prevention · CN

Funding

Shenzhen Science and Technology Innovation Committee JSGG20220301090202005
6 · The paper itself

Abstract

On 14 March 2022, China's tech hub Shenzhen, a mega-city with more than 18 million inhabitants, imposed a one-week citywide lockdown immediately after it observed a surge in infections. We assessed the effect of this one-week lockdown, coupled with mass testing, on reducing the daily number of new confirmed cases and asymptomatic cases during the Omicron wave, using an interrupted time series analysis approach. Our analysis suggests that the one-week citywide lockdown in Shenzhen was effective at lowering both daily new confirmed cases and asymptomatic cases during the Omicron wave. Early detection ensures timely isolation and treatment of infected patients in designated hospitals, and therefore helps lower the prevalence of confirmed cases and asymptomatic cases. Our findings of the immediate increase in asymptomatic cases after lockdown warrant further verifications in other city epidemic scenarios.

Indexed as

asymptomatic casesinfectionslockdownomicron epidemic

Identifiers

PMID36141337
PMCPMC9498528
OpenAlexW4294953497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.